Melanoma, PD-L1, CD274, p53, TP53, JAK2BackgroundImmune checkpoint inhibition and in particular anti-PD-1 immunotherapy have revolutionized the treatment of advanced melanoma. In this regard, higher tumoral PD-L1 protein (gene name: CD274) expression is associated with better clinical response and...
Cited in 15 publications. IFN-gamma R1 antibody for WB, IHC, IP, ELISA and reacts with human.
Release of Exosomal PD-L1 in Bone and Soft Tissue Sarcomas and Its Relationship to Radiotherapy Authors - Keisuke Yoshida View Article human serum Oncoimmunology Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma. Authors - Yaru Feng View Article human...
DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion. Authors - Baiwen Chen View Article human WB Cancer Commun (Lond) MAGE-C3 promotes cancer metastasis by inducing epithelial-mesenchymal transition and immunosuppression in esophageal squamous cell carcinoma. Authors - Qin...
摘要: The disclosure provides methods for treating lung cancer (e.g., non-small cell lung cancer) with an anti-PD-L1 antibody in a patient identified using a polynucleotide or polypeptide marker of the disclosure: CXCL9, KRT8, TRIM29, and/or IFNgamma....
pfaltzand&bauer/pfaltzandbauer | proteos | Quanta Biosciences | Prozomix | precision biologic | promabsci | phoenixsongs biologicals | phoenixsongsbio | Omni International | Oriental Yeast | ohio valley specialty | NBS-C BioScience | nanotemper | maravai lifesciences | NANOSOFT POLYMERS | mikrogen...
While targeted therapy and immunotherapy with checkpoint inhibitors have significantly decreased the mortality rate of this disease, advanced melanoma remains a therapeutic challenge. Here, we confirmed that interferon-gamma (IFN-纬)-induced PD-L1 expression in melanoma cell lines. Thi...
Results demonstrated that beta 3-AR antagonism lead to an immune response reactivation, partially dependent on the PD-1/PD-L1 signaling axis involvement. Indeed, beta 3-AR blockade on tumor-infiltrating lymphocytes (TILs) dampened their ability to secrete IFN-gamma, which in turn reduced the PD...
Taken together, these results suggest a two‐faceted nature of BRAF inhibition‐associated immunomodulatory effects: an early immunostimulatory activity, mediated at least in part by decreased PD‐L1 expression, and a delayed immunosuppressive effect associated with Gal‐1 induction. Importantly, our ...
METHODS FOR IDENTIFYING PATIENTS RESPONSIVE TO ANTI-PD-L1 ANTIBODY THERAPY USING MARKERS (CXCL9, KRT8.TRIM29, AND IFNGAMMA)The disclosure provides methods for treating lung cancer (e.g., non-small cell lung cancer) with an anti-PD-Llantibody in a patient identified using a polynucleotide or...